These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 12021219

  • 1. Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET Trial.
    Stone GW, Moliterno DJ, Bertrand M, Neumann FJ, Herrmann HC, Powers ER, Grines CL, Moses JW, Cohen DJ, Cohen EA, Cohen M, Wolski K, DiBattiste PM, Topol EJ.
    Circulation; 2002 May 21; 105(20):2347-54. PubMed ID: 12021219
    [Abstract] [Full Text] [Related]

  • 2. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, Cohen EA, Bertrand M, Neumann FJ, Stone GW, DiBattiste PM, Demopoulos L, TARGET Investigators. Do Tirofiban and ReoPro Give Similar Efficacy Trial.
    N Engl J Med; 2001 Jun 21; 344(25):1888-94. PubMed ID: 11419425
    [Abstract] [Full Text] [Related]

  • 3. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA, Rossi M, Menozzi A, Buratti S, Brennan DM, Moliterno DJ, Topol EJ, Ardissino D.
    Circulation; 2004 May 11; 109(18):2203-6. PubMed ID: 15117843
    [Abstract] [Full Text] [Related]

  • 4. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up.
    Roffi M, Moliterno DJ, Meier B, Powers ER, Grines CL, DiBattiste PM, Herrmann HC, Bertrand M, Harris KE, Demopoulos LA, Topol EJ, TARGET Investigators.
    Circulation; 2002 Jun 11; 105(23):2730-6. PubMed ID: 12057986
    [Abstract] [Full Text] [Related]

  • 5. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 6. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, de Cesare N, Rodriguez AE, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R, Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators.
    JAMA; 2008 Apr 16; 299(15):1788-99. PubMed ID: 18375998
    [Abstract] [Full Text] [Related]

  • 7. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
    Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari R, STRATEGY Investigators.
    JAMA; 2005 May 04; 293(17):2109-17. PubMed ID: 15870414
    [Abstract] [Full Text] [Related]

  • 8. Safety of glycoprotein IIb-IIIa inhibitors: A heart surgeon's perspective.
    Dyke CM.
    Am Heart J; 1999 Oct 04; 138(4 Pt 2):307-16. PubMed ID: 10502236
    [Abstract] [Full Text] [Related]

  • 9. Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
    Ross MJ, Herrmann HC, Moliterno DJ, Blankenship JC, Demopoulos L, DiBattiste PM, Ellis SG, Ghazzal Z, Martin JL, White J, Topol EJ.
    J Am Coll Cardiol; 2003 Sep 17; 42(6):981-8. PubMed ID: 13678916
    [Abstract] [Full Text] [Related]

  • 10. A direct comparison of tirofiban and abciximab during percutaneous coronary revascularization and stent placement: rationale and design of the TARGET study.
    Moliterno DJ, Topol EJ.
    Am Heart J; 2000 Nov 17; 140(5):722-6. PubMed ID: 11054616
    [Abstract] [Full Text] [Related]

  • 11. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ, TENACITY Steering Committee and Investigators.
    Catheter Cardiovasc Interv; 2011 Jun 01; 77(7):1001-9. PubMed ID: 21598351
    [Abstract] [Full Text] [Related]

  • 12. Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
    Ciccone A, Motto C, Abraha I, Cozzolino F, Santilli I.
    Cochrane Database Syst Rev; 2014 Mar 08; (3):CD005208. PubMed ID: 24609741
    [Abstract] [Full Text] [Related]

  • 13. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Bhatt DL, Topol EJ.
    JAMA; 2000 Sep 27; 284(12):1549-58. PubMed ID: 11000650
    [Abstract] [Full Text] [Related]

  • 14. A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
    Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.
    Circ Cardiovasc Interv; 2009 Jun 27; 2(3):230-6. PubMed ID: 20031720
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
    Holmes LE, Gupta R, Rajendran S, Luu J, French JK, Juergens CP.
    Cardiovasc Ther; 2016 Oct 27; 34(5):330-6. PubMed ID: 27327862
    [Abstract] [Full Text] [Related]

  • 16. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T, McGavin JK, Goa KL.
    Am J Cardiovasc Drugs; 2003 Oct 27; 3(5):381-6. PubMed ID: 14728074
    [Abstract] [Full Text] [Related]

  • 17. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB, Newman AR, Raco DL.
    Am Heart J; 1999 Jul 27; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [Abstract] [Full Text] [Related]

  • 18. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation.
    Ibbotson T, McGavin JK, Goa KL.
    Drugs; 2003 Jul 27; 63(11):1121-63. PubMed ID: 12749745
    [Abstract] [Full Text] [Related]

  • 19. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study.
    Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, Neumann FJ, Ardissino D, Bassand JP, Borzi L, Yeung AC, Harris KA, Demopoulos LA, Topol EJ, TARGET investigators.
    Lancet; 2002 Aug 03; 360(9330):355-60. PubMed ID: 12241774
    [Abstract] [Full Text] [Related]

  • 20. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.
    Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ.
    Circulation; 1998 Aug 25; 98(8):734-41. PubMed ID: 9727542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.